Logos Global Management’s Century Therapeutics IPSC Stock Holding History

Logos Global Management’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-460,075	Closed	-$4.55M	–	45
2022 Q3	$4.55M	Sell	460,075 -16,484	-3%	-$174K	0.56%	29
2022 Q2	$4M	Sell	476,559 -73,700	-13%	-$723K	0.73%	20
2022 Q1	$6.93M	Sell	550,259 -63,836	-10%	-$846K	0.9%	26
2021 Q4	$9.74M	Sell	614,095 -25,000	-4%	-$470K	1%	27
2021 Q3	$16.1M	Sell	639,095 -350,000	-35%	-$9.47M	1.16%	27
2021 Q2	$29M	Buy	+989,095	New	+$25.1M	2.44%	16

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Logos Global Management's IPSC Position: Q4 2022 in Review

Logos Global Management sold out of Century Therapeutics (IPSC) in Q4 2022, closing a stake of 460,075 shares — an estimated $4.55M sold.

Logos Global Management first reported a position in IPSC in Q2 2021 and held it in 6 quarters. The position peaked at $29M in Q2 2021. 65 funds tracked by Wall St. Rank hold IPSC as of Q4 2022.

Logos Global Management reported no remaining Century Therapeutics position as of Q4 2022 after selling out during the quarter.
Logos Global Management sold 460,075 Century Therapeutics shares in Q4 2022, an estimated $4.55M.
Logos Global Management first reported a position in Century Therapeutics in Q2 2021 and held it in 6 quarters.
Logos Global Management's Century Therapeutics position peaked at $29M in Q2 2021.
65 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2022.

Based on Logos Global Management's 13F filing for Q4 2022, filed 14 Feb 2023.